TMPRSS2-ERG fusion protein activates a transcriptional program that contributes to prostate oncogenesis through upregulation of the expression of some key genes including MYC, EZH2 and SOX9 and repression of NKX3 expression. The gene discussed is ERG; the disease is medical procedure.